NEW YORK--(BUSINESS WIRE)--May 22, 2012-- New York Genome Center (NYGC) today announced the formal commencement of their collaborative relationship with Illumina, initiated in November 2011, when Illumina was selected as the Center's lead sequencing technology provider. As a next step in this collaboration, the Center will begin taking delivery of Illumina HiSeq 2000 and 2500 sequencing systems, creating the foundation for its pilot lab operations, which will commence in Manhattan this summer.
Through this initiative, NYGC and Illumina are enabling a unique, fully integrated collaboration of leading academic and research centers and market leaders in healthcare and technology. As part of this novel model, NYGC and Illumina will partner with NYGC's Institutional Founding Members, which represent hundreds of academic and medical experts and multiple disease focuses. Illumina will provide NYGC with early access to key new products, its long track record of innovation, and its industry leading expertise.
"At NYGC, we are committed to supporting and accelerating state-of-the-art research with the very latest technologies, both from Illumina and other providers," describes Nancy J. Kelley, JD, MPP, Founding Executive Director of the New York Genome Center. "Delivery of the new Illumina systems represents a major step towards that goal.
As part of our Innovation Center, we also intend to fund additional purchases of 'next-next gen' sequencing technology, ensuring our member scientists always have access to the innovative tools they need to support their research and ultimately make a difference for patients." NYGC's sequencing, bioinformatics, and data warehousing services are available currently only to its Institutional Founding Members and select launch collaborators. Additional services and consulting will be available more broadly to other organizations when the permanent facility opens in early 2013.
"The field of genomic medicine is evolving rapidly, and the technology supporting this research must be powerful and flexible," said Jay Flatley, Illumina's President and CEO. "We are proud to provide the core sequencing technology for the NYGC and look forward to our ongoing collaboration and commitment to create a platform for transforming healthcare." About the New York Genome Center Founded in August 2010, NYGC is an independent non-profit that brings together the expertise and resources of world-class universities, medical centers, technology partners, pharmaceutical companies, and private philanthropists that are engaged in a cooperative effort to transform medical research and clinical care. NYGC's Institutional Founding Members include Cold Spring Harbor Laboratory, Columbia University, Cornell University/Weill Cornell Medical College, The Jackson Laboratory, Memorial Sloan-Kettering Cancer Center, Mount Sinai Medical Center, NewYork-Presbyterian Hospital, New York University/NYU School of Medicine, North Shore-LIJ Health System, The Rockefeller University, and Stony Brook University. The Hospital for Special Surgery is an Associate Founding Member.
The vision of NYGC is to serve as a transformational catalyst for the future of science and medicine by creating an intellectually vibrant collaboration among the biomedical and research communities in New York. NYGC intends to become one of the largest genomic facilities in North America, establishing an unprecedented, large-scale collaborative venture in genomic medicine. The NYGC model facilitates adoption of personalized medicine through its Institutional Founding Members that collectively treat millions of patients each year; drives therapeutic and diagnostic product development by connecting technology collaborators and the pharmaceutical industry directly to researchers and clinicians at the front lines of discovery; and accelerates the entire translational process by linking all the stakeholders in information-enabled common projects.
Website: www.nygenome.orgFacebook: http://www.facebook.com/nygenomeTwitter: @nygenome About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. Illumina also provide tools and services that are fueling advances in consumer genomics and diagnostics. The Company's technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
CONTACT: Media contacts: The TASC Group Larry Kopp / Kamian Allen Ph: 646-723-4344 / C: 212-671-0892 firstname.lastname@example.orgemail@example.com or Trade: Feinstein Kean Healthcare Lynn Blenkhorn, 508-851-0930 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS RESEARCH SCIENCE SOURCE: New York Genome Center Copyright Business Wire 2012 PUB: 05/22/2012 07:30 AM/DISC: 05/22/2012 07:30 AM http://www.businesswire.com/news/home/20120522005495/